Background
Methods
Study setting and design
Primary exposure and outcomes
Other covariates
Statistical analysis
Results
Baseline socio-demographic Characteristics of SARS-CoV-2 PCR-confirmed cases
Non-Hispanic White (n = 3346) | Non-Hispanic Black (n = 3049) | Non-Hispanic (n = 7348) | Hispanic (n = 4372) | |
---|---|---|---|---|
Demographics – n (%) | ||||
Age – mean (SD) | 51.7 (20.1) | 46.0 (18.1) a | 48.7 (19.2) | 44.0 (17.4) a |
Age ≤ 50 | 1582 (47.3) | 1825 (59.9) a | 4008 (54.5) | 3340 (76.4) a |
Females | 1792 (53.6) | 1837 (60.2) a | 4164 (56.7) | 2398 (54.8) |
Insurance Type | ||||
Commercial | 1736 (51.9) | 1454 (47.7) a | 3738 (50.9) | 1911 (43.7) a |
Medicare | 892 (26.7) | 567 (18.6) | 1605 (21.8) | 574 (13.1) |
Medicaid | 98 (2.9) | 227 (7.4) | 349 (4.7) | 380 (8.7) |
Self-Pay | 507 (15.2) | 729 (23.9) | 1449 (19.7) | 1452 (33.2) |
Other | 113 (3.4) | 72 (2.4) | 207 (2.8) | 55 (1.3) |
Household Income (USD), Median (IQR) | 75,793 (59,104 – 102,008) | 63,489 (46,801 – 76,163) a | 68,318 (52,825 – 97,681) | 59,104 (46,300 – 75,793) a |
Population Density (per square mile), Median (IQR) | 2741.6 (1162.5–4264.5) | 3256.8 (2040.7–4575) a | 2883.9 (1504–4384.8) | 3380.9 (1683.5–4384.8) a |
Coexisting Conditions / Prior Vaccinations – n (%) | ||||
CCI Total, Median (IQR) | 2 (0–4) | 1 (0–3) a | 1 (0–4) | 1 (0–2) a |
Charlson Comorbidities – n (%) | ||||
Myocardial Infarction | 263 (7.9) | 224 (7.3) | 530 (7.2) | 156 (3.6) a |
Congestive Heart Failure | 334 (10.0) | 328 (10.8) | 711 (9.7) | 202 (4.6) a |
Peripheral Vascular Disease | 328 (9.8) | 200 (6.6) a | 570 (7.8) | 182 (4.2) a |
CVA / TIA | 294 (8.8) | 259 (8.5) | 599 (8.2) | 186 (4.3) a |
Dementia | 179 (5.3) | 115 (3.8) a | 317 (4.3) | 41 (0.9) a |
COPD | 712 (21.3) | 589 (19.3) | 1409 (19.2) | 465 (10.6) a |
Connective Tissue Disease | 91 (2.7) | 72 (2.4) | 177 (2.4) | 71 (1.6) a |
Peptic Ulcer | 83 (2.5) | 51 (1.7) a | 147 (2.0) | 58 (1.3) a |
Liver Disease (Mild) | 238 (7.1) | 123 (4.0) a | 410 (5.6) | 224 (5.1) |
Liver Disease (Moderate to Severe) | 34 (1.0) | 12 (0.4) a | 48 (0.7) | 34 (0.8) |
Diabetes w/o Complications | 590 (17.6) | 769 (25.2) a | 1541 (21.0) | 978 (22.4) |
Diabetes with Complications | 199 (5.9) | 293 (9.6) a | 538 (7.3) | 219 (5.0) a |
Hemiplegia | 40 (1.2) | 40 (1.3) | 87 (1.2) | 27 (0.6) a |
CKD (Mild to Moderate) | 109 (3.3) | 152 (5.0) a | 283 (3.9) | 155 (3.5) |
Solid Tumor (Localized) | 278 (8.3) | 131 (4.3) a | 438 (6.0) | 132 (3.0) a |
Solid Tumor (Metastatic) | 214 (6.4) | 97 (3.2) a | 331 (4.5) | 99 (2.3) a |
AIDS | 14 (0.4) | 41 (1.3) a | 56 (0.8) | 15 (0.3) a |
BMI – mean (SD) | 29.8 (7.2) | 32.2 (8.2) a | 30.6 (7.7) | 31.7 (7.4) a |
Obesity | 777 (23.2) | 721 (23.6) | 1614 (22.0) | 808 (18.5) a |
Hypertension | 1441 (43.1) | 1454 (47.7) a | 3197 (43.5) | 1380 (31.6) a |
Hyperlipidemia | 1093 (32.7) | 826 (27.1) a | 2182 (19.7) | 925 (21.2) a |
Asthma | 374 (11.2) | 365 (12.0) | 811 (11.0) | 270 (6.2) a |
Smoking (Current/Former) | 829 (24.8) | 577 (18.9) a | 1509 (20.5) | 607 (13.9) a |
Prior Vaccinationb | ||||
Influenza | 424/626 (67.7) | 370/650 (56.9) a | 861/1382 (62.3) | 322/544 (59.2) a |
Pneumonia | 527/1064 (49.5) | 396/1047 (37.8) a | 996/2323 (42.9) | 353/1191 (29.6) a |
Hospitalized | 966 (28.9) | 937 (30.7) | 2115 (28.8) | 1366 (31.2) a |
Racial and ethnic differences in demographic, clinical, and outcome Characteristics among hospitalized COVID-19 patients
Non-Hispanic White (n = 966) | Non-Hispanic Black (n = 937) | Non-Hispanic (n = 2115) | Hispanic (n = 1366) | |
---|---|---|---|---|
Demographic Characteristics and Comorbidity Index – n (%) | ||||
Age – mean (SD) | 65.0 (17.6) | 59.0 (16.4) a | 62.1 (17.3) | 54.2 (16.3) a |
Female | 437 (45.2) | 513 (54.7) a | 1030 (48.7) | 642 (47.0) |
Insurance Type | ||||
Commercial | 301 (31.2) | 332 (35.4) a | 718 (33.9) | 447 (32.7) a |
Medicare | 478 (49.5) | 388 (41.4) | 956 (45.2) | 377 (27.6) |
Medicaid | 27 (2.8) | 50 (5.3) | 82 (3.9) | 122 (8.9) |
Self-Pay | 90 (9.3) | 122 (13.0) | 231 (10.9) | 386 (28.3) |
Other | 70 (7.2) | 45 (4.8) | 128 (6.1) | 34 (2.5) |
Household Income (USD), Median (IQR) | 68,318 (56,974 – 94,829.3) | 56,974 (44,422 – 70,658) a | 65,805 (48,790 – 86,034) | 56,288 (44,422 – 70,324) a |
Population Density (per square mile), Median (IQR) | 2493.9 (812.2–4081.3) | 3256.8 (1925.8–4789.7) a | 2849.1 (1439.1–4304.3) | 3513.1 (1823.2–4988.2) a |
CCI Total, Median (IQR) | 5 (2–8) | 3 (1–7) a | 4 (2–7) | 2 (1–4) a |
Vital Signs at Hospital Admission – n (%) | ||||
SBP (mmHg) – mean (SD) | 133.8 (19.3) | 136.0 (20.8) a | 134.4 (19.9) | 131.7 (18.9) a |
DBP (mmHg) – mean (SD) | 71.5 (9.3) | 74.1 (10.6) a | 72.6 (9.9) | 72.2 (9.3) |
Respiratory Rate ≥ 24 breath / min | 172 (17.8) | 162 (17.3) | 384 (18.2) | 350 (25.6) a |
Temperature ≥ 38 °C | 31 (3.2) | 80 (8.5) a | 129 (6.1) | 89 (6.5) |
Oxygen Saturation < 94% | 176 (18.2) | 111 (11.8) a | 335 (15.8) | 262 (19.2) a |
Laboratory Parameters – n (%)b | ||||
WBC count < 4000/μl | 79/964 (8.2) | 63/935 (6.7) | 159/2111 (7.5) | 74/1361 (5.4) a |
Lymphocytes < 20% | 665/964 (69.0) | 554/934 (59.3) a | 1383/2110 (65.5) | 938/1360 (69.0) a |
Platelet count < 150,000/μl | 148/964 (15.4) | 110/935 (11.8) a | 284/2111 (13.5) | 145/1361 (10.7) a |
B-natriuretic peptide > 100 pg/ml, | 296/696 (42.5) | 213/646 (33.0) a | 566/1500 (37.7) | 245/954 (25.7) a |
Procalcitonin > 0.25 ng/ml | 149/319 (46.7) | 189/327 (57.8) a | 375/726 (51.7) | 248/526 (47.1) |
Troponin ≥0.06 ng/ml | 206/607 (33.9) | 224/618 (36.2) | 475/1364 (34.8) | 186/633 (29.4) a |
Aspartate aminotransferase > 40 U/l | 426/938 (45.4) | 467/919 (50.8) a | 1029/2068 (49.8) | 750/1337 (56.1) a |
Alanine aminotransferase > 40 U/l | 322/936 (34.4) | 317/917 (34.6) | 744/2064 (36.0) | 693/1335 (51.9) a |
Total Bilirubin ≥1.2 mg/dl | 39/861 (4.5) | 43/865 (5.0) | 88/1930 (4.6) | 40/1254 (3.2) |
C-reactive protein > 8.2 ng/ml | 750/802 (93.5) | 725/777 (93.3) | 1661/1775 (93.6) | 1167/1199 (97.3) a |
Ferritin level > 3000 ng/ml | 35/803 (4.4) | 70/774 (9.0) a | 114/1774 (6.4) | 65/1228 (5.3) |
D-dimer > 0.5 μg/ml | 670/775 (86.5) | 681/766 (88.9) | 1511/1730 (87.3) | 985/1201 (82.0) a |
Creatinine > 1.5 mg/dl | 154/956 (16.1) | 255/929 (27.4) a | 441/2097 (21.0) | 159/1346 (11.8) a |
Venous Lactate > 2.2 mmol/l | 141/714 (19.7) | 122/669 (18.2) | 301/1557 (19.3) | 191/972 (19.7) |
Level of Hospital Care – n (%) | ||||
ICU Stay – n (%) | 284 (29.4) | 297 (31.7) | 655 (31.0) | 432 (31.6) |
On Ventilator – n (%) | 156 (16.1) | 162 (17.3) | 361 (17.1) | 212 (15.5) |
Days on Ventilator, median (IQR)c | 6.7 (2.5–13.3) | 6.9 (2.9–15.2) | 6.9 (2.8–14.8) | 8.0 (3.6–14.3) |
Hospital Complications – n (%) | ||||
Pneumonia | 600 (62.1) | 617 (65.8) | 1366 (64.6) | 958 (70.1) a |
ARDS | 35 (3.6) | 51 (5.4) | 109 (5.2) | 80 (5.9) |
Bronchitis | 12 (1.2) | 14 (1.5) | 27 (1.3) | 16 (1.2) |
Lower Respiratory Tract Infection | 12 (1.2) | 11 (1.2) | 24 (1.1) | 9 (0.7) |
Acute Renal Injury | 229 (23.7) | 303 (32.3) a | 580 (27.4) | 191 (14.0) a |
Acute Hepatic Injury | 16 (1.7) | 9 (1.0) | 28 (1.3) | 18 (1.3) |
Cardiomyopathy or CHF | 151 (15.6) | 149 (15.9) | 321 (15.2) | 96 (7.0) a |
Hypoxic Respiratory Failure | 347 (35.9) | 330 (35.2) | 764 (36.1) | 589 (43.1) a |
Therapeutics – n (%) | ||||
Hydroxychloroquine | 109 (11.3) | 123 (13.1) | 258 (12.2) | 101 (7.4) a |
Ribavirin | 33 (3.4) | 29 (3.1) | 71 (3.4) | 31 (2.3) |
Azithromycin | 124 (12.8) | 150 (16.0) | 312 (14.8) | 208 (15.2) |
Lopinavir/Ritonavir | 12 (1.2) | 8 (0.9) | 22 (1.0) | 2 (0.1) a |
Remdesivir | 147 (15.2) | 139 (14.8) | 333 (15.7) | 345 (25.3) a |
Tocilizumab | 146 (15.1) | 149 (15.9) | 354 (16.7) | 320 (23.4) a |
Antithrombotic | 387 (40.1) | 367 (39.2) | 830 (39.2) | 329 (24.1) a |
Anticoagulants | 874 (90.5) | 827 (88.3) | 1897 (89.7) | 1246 (91.2) |
Dexamethasone | 389 (40.3) | 360 (38.4) | 841 (39.8) | 681 (49.9) a |
Outcomes – n (%) | ||||
Currently Hospitalized | 182 (18.8) | 171 (18.2) | 391 (18.5) | 256 (18.7) |
Died | 84 (8.7) | 58 (6.2) a | 164 (7.8) | 66 (4.8) a |
Died (among discharged or died) | 84/784 (10.7) | 58/766 (7.6) a | 164/1724 (9.5) | 66/1110 (5.9) a |
Died (ICU admits excl. Currently hospitalized)d | 60/213 (28.2) | 44/209 (21.1) a | 124/478 (25.9) | 62/304 (20.4) a |
Length of Stay Days – median (IQR)e | 7 (3–15) | 6 (3–12) | 6 (3–13) | 5 (3–10) |
Racial and ethnic differences in likelihood of hospitalization among SARS-CoV-2 positive patients
Model 1 OR (95% CI)a (n = 6395) | Model 2 OR (95% CI)a (n = 6345) | Model 3 OR (95% CI)a (n = 6344) | |
Model AICb | 6291.8 | 6204.9 | 5804.8 |
Non-Hispanic Black (vs. NHW) | 1.74 (1.53, 1.98) | 1.61 (1.41, 1.84) | 1.42 (1.24, 1.63) |
Age, in 5-year units | 1.30 (1.27, 1.34) | 1.31 (1.28, 1.34) | 1.18 (1.15, 1.22) |
Female (vs. Male) | 0.64 (0.57, 0.72) | 0.63 (0.56, 0.71) | 0.63 (0.55, 0.71) |
Insurance Type | |||
Commercial | Reference | Reference | Reference |
Medicare | 1.66 (1.39, 1.98) | 1.58 (1.32, 1.89) | 1.14 (0.94, 1.39) |
Medicaid | 2.34 (1.72, 3.15) | 2.22 (1.63, 3.00) | 2.05 (1.48, 2.83) |
Self-Pay | 0.98 (0.81, 1.17) | 0.94 (0.78, 1.13) | 1.25 (1.03, 1.52) |
Residence: Low Income ZIP Codec | 1.51 (1.32, 1.72) | 1.41 (1.23, 1.62) | |
Residence: Population Dense ZIPd | 0.89 (0.78, 1.01) | 0.96 (0.84, 1.10) | |
Charlson Comorbidity Index Score | 1.15 (1.12, 1.19) | ||
Obesity | 1.50 (1.29, 1.74) | ||
Hypertension | 1.77 (1.51, 2.07) | ||
Smoking (Current/Former) | 0.94 (0.80, 1.10) | ||
Model 1 OR (95% CI)a (n = 11,720) | Model 2 OR (95% CI)a (n = 11,645) | Model 3 OR (95% CI)a (n = 11,642) | |
Model AICb | 11,692 | 11,520 | 10,858 |
Hispanic (vs. Non-Hispanic) | 1.57 (1.43, 1.73) | 1.47 (1.33, 1.61) | 1.61 (1.46, 1.78) |
Age, in 5-year units | 1.30 (1.28, 1.33) | 1.31 (1.29, 1.33) | 1.21 (1.18, 1.23) |
Female (vs. Male) | 0.63 (0.57, 0.68) | 0.62 (0.56, 0.67) | 0.58 (0.53, 0.64) |
Insurance Type | |||
Commercial | Reference | Reference | Reference |
Medicare | 1.70 (1.48, 1.95) | 1.63 (1.42, 1.87) | 1.23 (1.06, 1.42) |
Medicaid | 3.05 (2.49, 3.72) | 2.88 (2.35, 3.52) | 2.80 (2.26, 3.46) |
Self-Pay | 1.14 (1.02, 1.29) | 1.09 (0.97, 1.23) | 1.45 (1.28, 1.65) |
Residence: Low Income ZIPc | 1.56 (1.42, 1.72) | 1.48 (1.34, 1.64) | |
Residence: Population Dense ZIPd | 1.00 (0.91, 1.10) | 1.07 (0.97, 1.18) | |
Charlson Comorbidity Index Score | 1.12 (1.10, 1.15) | ||
Obesity | 1.62 (1.45, 1.82) | ||
Hypertension | 1.67 (1.49, 1.87) | ||
Smoking (Current/Former) | 0.86 (0.77, 0.98) |
Racial and ethnic differences in likelihood of death among hospitalized COVID-19 patients
Model 1 OR (95% CI)a (n = 1887) | Model 2 OR (95% CI)a (n = 1835) | Model 3 OR (95% CI)a (n = 1835) | |
Model AICb | 908.51 | 796.86 | 682.03 |
Non-Hispanic Black (vs. NHW) | 0.96 (0.65, 1.40) | 0.72 (0.47, 1.09) | 0.65 (0.40, 1.03) |
Demographic Factors | |||
Age, in 5-year units | 1.25 (1.16, 1.35) | 1.26 (1.16, 1.38) | 1.31 (1.20, 1.45) |
Female (vs. Male) | 0.82 (0.56, 1.18) | 1.13 (0.76, 1.69) | 1.00 (0.64, 1.56) |
Residence: Low Income ZIP Codec | 1.00 (0.69, 1.44) | 0.95 (0.64, 1.40) | 0.95 (0.62, 1.47) |
Charlson Comorbidity Index Score | 1.11 (1.05, 1.17) | 1.09 (1.03, 1.16) | 1.03 (0.96, 1.10) |
Obesity | 1.14 (0.76, 1.70) | 1.18 (0.77, 1.81) | 1.04 (0.65, 1.67) |
Hypertension | 1.24 (0.68, 2.44) | 0.91 (0.48, 1.85) | 0.81 (0.39, 1.77) |
Smoking (Current/Former) | 1.14 (0.77, 1.67) | 1.04 (0.69, 1.57) | 1.11 (0.71, 1.74) |
Vital Signs | |||
Respiratory Rate ≥ 24 breath / min | 1.80 (1.16, 2.75) | 1.29 (0.79, 2.08) | |
Oxygen Saturation < 94% | 1.94 (1.21, 3.09) | 1.75 (1.03, 2.93) | |
Laboratory Parameters | |||
Lymphocytes < 20% | 3.05 (1.77, 5.57) | 2.30 (1.27, 4.41) | |
Platelet count < 150,000/μl | 2.02 (1.26, 3.20) | 1.93 (1.14, 3.25) | |
Aspartate aminotransferase > 40 U/l | 2.32 (1.46, 3.72) | 2.18 (1.31, 3.66) | |
Alanine aminotransferase > 40 U/l | 1.04 (0.66, 1.66) | 0.76 (0.45, 1.28) | |
Creatinine > 1.5 mg/dl | 2.99 (1.97, 4.55) | 2.20 (1.37, 3.55) | |
Hospital Complications | |||
Pneumonia | 1.04 (0.58, 1.90) | ||
ARDS | 5.53 (2.60, 11.91) | ||
Hypoxic Respiratory Failure | 3.68 (2.15, 6.45) | ||
Acute Renal Injury | 1.88 (1.17, 3.01) | ||
Acute Hepatic Injury | 1.23 (0.40, 3.61) | ||
Cardiomyopathy or CHF | 1.10 (0.67, 1.77) | ||
Therapeutics | 0.56 (0.26, 1.12) | ||
Remdesivir | 0.56 (0.26, 1.12) | ||
Dexamethasone | 0.64 (0.40, 1.00) | ||
ICU Admission | 3.43 (2.08, 5.72) | ||
Model 1 OR (95% CI)a (n = 3454) | Model 2 OR (95% CI)a (n = 3369) | Model 3 OR (95% CI)a (n = 3369) | |
Model AICb | 1468.1 | 1261.7 | 1012.8 |
Hispanic (vs. Non-Hispanic) | 1.12 (0.80, 1.54) | 0.95 (0.67, 1.34) | 0.89 (0.59, 1.31) |
Demographic Factors | |||
Age, in 5-year units | 1.27 (1.20, 1.35) | 1.29 (1.21, 1.39) | 1.35 (1.25, 1.46) |
Female (vs. Male) | 0.78 (0.58, 1.04) | 1.09 (0.80, 1.49) | 0.93 (0.65, 1.32) |
Residence: Low Income ZIP Codec | 0.95 (0.72, 1.28) | 0.87 (0.64, 1.18) | 0.88 (0.63, 1.25) |
Charlson Comorbidity Index Score | 1.11 (1.06, 1.16) | 1.09 (1.04, 1.14) | 1.02 (0.96, 1.08) |
Obesity | 1.30 (0.94, 1.78) | 1.34 (0.95, 1.88) | 1.08 (0.73, 1.58) |
Hypertension | 1.38 (0.88, 2.21) | 1.09 (0.68, 1.78) | 0.88 (0.52, 1.54) |
Smoking (Current/Former) | 1.16 (0.84, 1.60) | 1.12 (0.79, 1.58) | 1.25 (0.85, 1.84) |
Vital Signs | |||
Respiratory Rate ≥ 24 breath / min | 1.44 (1.02, 2.01) | 1.13 (0.77, 1.66) | |
Oxygen Saturation < 94% | 2.33 (1.64, 3.31) | 1.90 (1.27, 2.84) | |
Laboratory Parameters | |||
Lymphocytes < 20% | 3.45 (2.14, 5.86) | 2.31 (1.36, 4.08) | |
Platelet count < 150,000/μl | 1.99 (1.37, 2.86) | 1.60 (1.03, 2.45) | |
Aspartate aminotransferase > 40 U/l | 2.88 (1.96, 4.27) | 2.47 (1.61, 3.82) | |
Alanine aminotransferase > 40 U/l | 1.14 (0.80, 1.64) | 0.74 (0.49, 1.13) | |
Creatinine > 1.5 mg/dl | 3.04 (2.18, 4.23) | 1.98 (1.35, 2.89) | |
Hospital Complications | |||
Pneumonia | 1.00 (0.60, 1.67) | ||
ARDS | 7.02 (3.82, 13.12) | ||
Hypoxic Respiratory Failure | 3.67 (2.27, 6.07) | ||
Acute Renal Injury | 2.04 (1.40, 2.97) | ||
Acute Hepatic Injury | 3.31 (1.46, 7.58) | ||
Cardiomyopathy or CHF | 1.21 (0.80, 1.80) | ||
Therapeutics | |||
Remdesivir | 0.57 (0.34, 0.95) | ||
Dexamethasone | 0.73 (0.51, 1.06) | ||
ICU Admission | 4.55 (2.97, 7.08) |